To the Editor: Dyskeratosis congenita (DC) is a telomere biology disorder (TBD) associated with bone marrow failure (BMF) and the classic triad of reticulate skin pigmentation, nail dystrophy, and oral leukoplakia. Disease-causing variants in at least 11 telomere biology genes have been implicated in DC and exhibit autosomal dominant (AD), autosomal recessive (AR), and X-linked recessive (XLR) inheritance, as well as de novo occurrence (TERF1 interacting nuclear factor 2 gene [TINF2]). Patients with XLR, AR or TINF2 DC tend to manifest more severe hematologic outcomes than patients with AD DC. 1, 2 We sought to assess the sensitivity of the clinical triad for DC diagnosis, quantify additional mucocutaneous features, and examine the relationship between DC genotype and mucocutaneous phenotype.
This study included 60 patients with genetically proven DC in an institutional review boardeapproved longitudinal cohort study, NCT-00027274 (Table I) . 3 The prevalence of triad features and 8 additional mucocutaneous findings (adermatoglyphia, palmoplantar hyperkeratosis, hyperhidrosis, premature graying, scalp or eyelash hair loss, epiphora, and lash irritation/blepharitis) were elicited from comprehensive medical photographs and dermatology evaluations. Hematologic and mortality outcomes data were gathered prospectively.
Telomere length data were obtained for 58 of 60 patients as previously described. 4 Patients with XLR/AR DC and AD DC were compared. Because TINF2 variants can be inherited as AD or de novo variants and typically have severe phenotypes, patients with TINF2 DC were excluded from the AD group and analyzed separately. Although triad features were most common, 6 nontriad features (epiphora, adermatoglyphia, early graying, palmoplantar hyperkeratosis, eyelash loss, and hair loss from scalp) were present in more than 20% of the cohort (Fig 1, A) . The complete clinical triad manifested in only 37% of patients (22 of 60), whereas 10% (6 of 60) lacked all triad features. Patients with higher numbers of triad and total mucocutaneous features were more likely to have AR DC or heterozygous TINF2 mutations (P \ .01, chi-square test). All 6 patients lacking any triad features had AD DC. The number of triad features was strongly inversely associated with telomere length (P ¼ .002). Patients with 2 or 3 triad features had a greater cumulative incidence of BMF compared with patients with 0 or 1 triad features (Fig 1, B) (P \ .0001). A higher number of total features was also associated with cumulative incidence of BMF and overall mortality (P \.0001).
This study specifically focused on mucocutaneous phenotypes in a large cohort of patients with DC. Severe mucocutaneous phenotypes, as defined by the number of triad features and additional findings, are associated with higher-risk genotypes and poorer prognosis compared with milder mucocutaneous phenotypes. We that believe careful detection of all mucocutaneous features of DC is important for early referral, confirmatory testing, and appropriate clinical management. Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center
To the Editor: Rituximab has been widely used for treatment-refractory pemphigus, but the experience of its use as a first-line steroid-sparing agent is limited. 1, 2 In this retrospective study we assessed whether use of rituximab early in the disease course would improve the long-term clinical outcome.
All patients with pemphigus vulgaris and pemphigus foliaceus who were evaluated between January 2008 and December 2016 at our institute and systematically treated with rituximab were included. Group A encompassed patients who received rituximab as a first-line steroid-sparing adjuvant within 6 months of diagnosis without any conventional immunosuppresants. Group B consisted of patients with disease activity who received rituximab after failing treatment with corticosteroids/conventional immunosuppressants or for relapse after them. Patients in both groups were treated with 2 infusions of 1000 mg of rituximab 2 weeks apart. Patients who relapsed or failed to achieve complete remission (CR) 3 in 6 months were re-treated with a single infusion (1000 mg) of rituximab. In addition, patients in both groups received oral corticosteroids in the form of a starting dose of prednisolone between 0.5 to 1 mg/kg, invariably with a quick taper and withdrawal of the corticosteroids within 6 months depending on the severity of the disease and clinical judgment.
The primary aim was to compare the efficacy between the 2 groups in terms of achieving CR off therapy. The secondary outcomes were CR when receiving minimal therapy, relapse rate, requirement of repeat infusions, and rituximab-related adverse events. 3 The baseline characteristics of the 2 groups are summarized in Table I . In all, 7 of 9 patients in group A (estimated cumulative rate, 87.5%) and 12 of 20 patients in group B (estimated cumulative rate, 66.2%) achieved CR off therapy (P ¼ .01). After accounting for the effect of disease duration, the hazard ratio between the 2 groups was still statistically significant (hazard ratio, 6.10; 95% confidence interval, 1.52-24.44; P ¼ .01).
When both minimal therapy and off therapy were considered, CR was achieved by 8 of 9 patients in group A (estimated cumulative rate, 100%) and 19 of 22 patients in group B (estimated cumulative rate, 92.9%) without any statistically significant difference (Table II) . Relapse was seen in 4 of 9 (44.4%) and 7 of 22 (31.8%) patients in groups A and B, respectively. Five of 9 patients in group A (55.6%) and 6 of 22 patients in group B (35.5%) were administered repeated infusions of rituximab, with 3 patients (33.3%) and 2 patients (9.1%), respectively, receiving 2 or more repeat infusions. No significant difference was found between the 2 groups regarding the time to first relapse (P ¼ .33).
